ZNTL
Zentalis Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.30
+7.98%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$2.40
From 52W high−65.20%
Volume2.73M
Market cap$217.75M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$2.40
From 52W high
−65.20%
Volume
2.73M
Market cap
$217.75M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.5x
P/E (TTM)
—
RSI (14)
34.3
MomentumView details →
1D Return
+7.98%
YTD Return
+70.00%
SummaryUpdated Jun 1, 2026
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in New York, New York. The company went public in April 2020 and focuses on discovering and developing small molecule therapeutics specifically designed to treat various forms of cancer. Zentalis operates in the highly specialized field of precision oncology, where it develops targeted therapies that aim to disrupt specific molecular pathways involved in cancer cell growth and survival.
Similar companies
Latest newsMore news →
Zentalis Pharmaceuticals, Inc. announced that interim overall survival data from the DENALI Part 1b study were published in an abstract for an upcoming ESMO Congress 2026 presentation.1d agoZentalis Pharmaceuticals announced the commencement of a proposed underwritten public offering of shares of its common stock and pre-funded warrants to purchase common stock.68d ago